Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
StemCyte InternationalTPE:4178 -2.39%7 Days Payable is 52.64 as of Mar. 2026, which is 18% below its 10-year median of 64.41. GuruFocus rates TPE:4178 with a GF Score™ of 7/100. The stock has 4 warning signs investors should review. Among 704 Biotechnology companies, StemCyte International ranks worse than 63.49% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:4178 vs VRTX, REGN, RVMD: Days Payable Comparison
For the Biotechnology subindustry, StemCyte International's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
StemCyte International Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, StemCyte International's Days Payable distribution charts can be found below:
* The bar in red indicates where StemCyte International's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
StemCyte International's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
StemCyte International (TPE:4178) has a Days Payable of 52.64 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on StemCyte International and its competitors. This is 18% below median its historical median of 64.41. Over the past decade, StemCyte International's Days Payable has ranged from 56.41 to 72.00. According to the industry distribution chart, StemCyte International ranks #447 out of 704 companies in the Biotechnology industry, placing it in the top 63.5%.
Is StemCyte International's Days Payable too high?
StemCyte International's current Days Payable of 52.64 is 18% below median its 10-year median of 64.41. Over the past 10 years, this metric has ranged from a low of 56.41 to a high of 72.00. The Biotechnology industry median Days Payable is 112.72. StemCyte International's value of 52.64 is 53.3% below this industry median. Based on the distribution chart, StemCyte International ranks #447 out of 704 companies in the Biotechnology industry, which is below the industry midpoint. Overall, StemCyte International has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does StemCyte International's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, StemCyte International ranks #447 out of 704 companies for Days Payable. This places StemCyte International in the lower half of its industry. The industry median Days Payable is 112.72. StemCyte International's value of 52.64 is 53.3% below this benchmark. Historically, StemCyte International's own Days Payable has ranged from 56.41 to 72.00 over the past decade. While the company's 10-year median is 64.41 vs. the industry median of 112.72, StemCyte International has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.72, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. StemCyte International's current Days Payable of 52.64 is 53.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on StemCyte International and its competitors. For the Biotechnology industry, the median Days Payable is 112.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. StemCyte International's current Days Payable is 52.64, which is 18% below median its own 10-year median of 64.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is StemCyte International stock overvalued right now?
StemCyte International (TPE:4178) has a current Days Payable of 52.64. The current Days Payable is 52.64, which is 18% below median its 10-year median of 64.41 and 53.3% below the Biotechnology industry median of 112.72. StemCyte International's overall GF Score™ is 7/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For StemCyte International (TPE:4178), the current Days Payable is 52.64 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
StemCyte International Ltd is engaged in developing new stem cell drugs and test, process, and store umbilical cord blood (UCB)-related cells. The company's main operating activities are providing umbilical cord blood collection, processing and storage services. Its reportable segments are the United States, Taiwan, and Others. The majority of revenue is derived from the United States.
7GF Score
Get the complete analysis for TPE:4178
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4178 has been successfully added to your 
